richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine.. following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv)..
.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018...
1.
.copyright 2018 npr. to see more, visit /www.npr.org/..